These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 21702122)

  • 1. [Progress in B-cell targeting therapy for the treatment of systemic lupus erythematosus].
    Tanaka Y
    J UOEH; 2011 Jun; 33(2):173-81. PubMed ID: 21702122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
    Reddy V; Jayne D; Close D; Isenberg D
    Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S2. PubMed ID: 23566295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
    Tanaka Y
    Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
    Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y
    J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell-targeted therapy for systemic lupus erythematosus: an update.
    Ding C; Foote S; Jones G
    BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.
    Marks SD; Tullus K
    Paediatr Drugs; 2007; 9(6):371-8. PubMed ID: 18052407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.
    Nakayamada S; Iwata S; Tanaka Y
    Int J Rheum Dis; 2015 Feb; 18(2):208-18. PubMed ID: 25557245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLE - Rituximab in lupus.
    Eisenberg R
    Arthritis Res Ther; 2003; 5(4):157-9. PubMed ID: 12823844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20).
    Eisenberg R
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):345-50. PubMed ID: 17214580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in systemic lupus erythematosus and lupus nephritis.
    Beckwith H; Lightstone L
    Nephron Clin Pract; 2014; 128(3-4):250-4. PubMed ID: 25471633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab and lupus--a promising pair?
    Ekö SL; van Vollenhoven RF
    Curr Rheumatol Rep; 2014; 16(9):444. PubMed ID: 25074032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
    Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
    BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell biomarkers of rituximab responses in systemic lupus erythematosus.
    Vital EM; Dass S; Buch MH; Henshaw K; Pease CT; Martin MF; Ponchel F; Rawstron AC; Emery P
    Arthritis Rheum; 2011 Oct; 63(10):3038-47. PubMed ID: 21618204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
    Merrill JT; Neuwelt CM; Wallace DJ; Shanahan JC; Latinis KM; Oates JC; Utset TO; Gordon C; Isenberg DA; Hsieh HJ; Zhang D; Brunetta PG
    Arthritis Rheum; 2010 Jan; 62(1):222-33. PubMed ID: 20039413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
    Anolik JH; Barnard J; Cappione A; Pugh-Bernard AE; Felgar RE; Looney RJ; Sanz I
    Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
    Md Yusof MY; Shaw D; El-Sherbiny YM; Dunn E; Rawstron AC; Emery P; Vital EM
    Ann Rheum Dis; 2017 Nov; 76(11):1829-1836. PubMed ID: 28684557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B Cell-Based Treatments in SLE: Past Experience and Current Directions.
    Liossis SC; Staveri C
    Curr Rheumatol Rep; 2017 Nov; 19(12):78. PubMed ID: 29101479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.